title: Targeted therapy of kidney cancer: keeping the art around the algorithms.
abstract: BACKGROUND
  Therapy for metastatic kidney cancer is actively evolving, particularly in the results of registration drug trials that have led to the approval of vascular endothelial growth factor pathway drugs such as sorafenib, sunitinib, pazopanib, bevacizumab, and axitinib, with focus on patients with good- or intermediate-risk criteria and clear cell histology. Mammalian target of rapamycin (mTOR) drugs such as everolimus and temsirolimus pivotal trials emphasize experiences in the setting of prior treatment or high-risk features. Interferon and interleukin 2 also are part of the treatment algorithms.
  
  
  METHODS
  The results of pivotal trials and the underlying context for the development of a cogent, cohesive treatment plan for an individual are reviewed, touching on decision points such as nephrectomy, metastasectomy, and medical initiation and discontinuation time points.
  
  
  RESULTS
  To the extent that these drug therapies are essential for achieving best outcomes for patients, these pivotal trial results and associated guidelines exist within a multidimensional, multidisciplinary context of many other disease features, comorbid features, and non-drug treatment decisions. Other dimensions include investigational targeted therapies, patient selection strategies, surgical strategies, and immunotherapies, some of which are in active development.
  
  
  CONCLUSIONS
  Clinicians should work toward the best use of drug sequencing and selection strategies based on core data derived from prospective randomized trials. To address individual patient needs, they should also recognize and emphasize individualized goals, to the extent that these are different from issues that were directly addressed in the trials.
authors.affiliation: Genitourinary Oncology Program, Moffitt Cancer Center, Tampa, FL 33612, USA. Mayer.Fishman@Moffitt.org
authors.forename: Mayer N
authors.initials: MN
authors.lastname: Fishman
mesh_terms: D000465:Algorithms; D002292:Carcinoma, Renal Cell / Q000378:metabolism / Q000628:therapy*; D002986:Clinical Trials as Topic; D003131:Combined Modality Therapy; D006801:Humans; D007680:Kidney Neoplasms / Q000378:metabolism / Q000628:therapy*; D058990:Molecular Targeted Therapy; D018579:Patient Selection; D011379:Prognosis